Navigation Links
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Date:6/9/2009

at Yale University and is board certified in Neurology.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics that address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.

The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's technology has been shown to increase oral bioavailability and inhibit penetration across the blood-brain barrier, an important potential advance for small molecule therapies. The product is being developed to treat opioid-induced constipation (OIC).

NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 study in patients with refractory solid tumors.

Nektar technology is used in nine approved partnered products in the U.S. or Europe today, including UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's technology platform, Nektar's pipeline of
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nektar Therapeutics Reports First Quarter 2009 Financial Results
2. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
4. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
5. Nektar Announces Retirement of Irwin Lerner from Board of Directors
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
8. Nektar Therapeutics to Webcast R&D Day on November 12th
9. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ...
(Date:12/24/2014)... December 23, 2014 On Friday, December ... the Omnibus and Continuing Resolution Appropriations Act of 2015, ... eligible to receive funding through the Congressionally Directed Medical ... (DoD). The Hydrocephalus Association (HA), working in conjunction with ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... SUNNYVALE, Calif., Sept. 15 Advanced Chemical,Transport, one ... announced the opening of a new location in ... its environmental services -- hazardous,biological and radioactive waste ... and environmental health and,safety outsourcing -- from the ...
... China, Sept. 15 3SBio Inc. (Nasdaq:,SSRX), a ... and marketing biopharmaceutical products, today,announced the results of ... of Shareholders held on September 12, 2008 (Friday) ... the Company,s shareholders re-elected Dr. Jing Lou,Liping Xu, ...
... CMS, Inc., an Elekta Company and,worldwide leader ... announced the commercial launch of its new 4D ... Focal product line that also includes FocalSim and,FocalPro, ... the,visualization and utilization of 4D image sets to ...
Cached Biology Technology:Advanced Chemical Transport Opens Merced Facility 2CMS, Inc., an Elekta Company, Announces Commercial Availability of Focal4D(TM) 2
(Date:12/19/2014)... Inc., the leading personal genetics company, today announced the publication ... of individuals from across the United States ... hundred years ago, the United States ... continents. This study illuminates how American history and the ongoing ...
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to current ... enables HITLAB to conduct regulated smart device and smart ... safety and research quality. "HITLAB is determined ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has ... Market 2015-2019" report to their offering. ... is a technology used for the identification of individuals. ... a person such as nose, jaw edges, mouth, and ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... them into adulthood and may render them more susceptible to ... new UBC study. A team led by UBC researchers ... healthy adults aged 25-40 years. Those who participated in ... circumstances related to income, education and occupation during the first ...
... of unicellular marine microorganisms that are not only a crucial ... fossils, which are found in abundance, provide scientists with an ... the history of the earth. Now, planktonic foraminifera ... have given up a secret of their very own. ...
... first time, the Society of Interventional Radiology has assembled ... artery embolization, a treatment directed toward a number of ... may occur due to the presence of uterine fibroids. ... "virtual" collection allows health care providers and the public ...
Cached Biology News:Early-life experience linked to chronic diseases later in life: UBC research 2Surviving mass extinction by leading a double life 2Avoiding hysterectomy: Major interventional radiology E-collection info available 2Avoiding hysterectomy: Major interventional radiology E-collection info available 3
... J. Karn (1995) This ... information and methods for the study of ... cycle; reverse transcriptase, ribonuclease H, integrase and ... RNA binding assays; Tat and Rev assays; ...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Tachykinin (H-2)...
Human GATA-2 Affinity Purified Polyclonal Ab...
Biology Products: